Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade

PCs are enriched in clinical responders to PD-1 blockade To test the hypothesis that B ...

Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG

Bayry, J. et al. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J. ...